2014


To access this material please log in or register

Register Authorize
2014/№4

Comparing antiplatelet effects of acetylsalicylic acid in different forms

Lomakin N. V., Rusanova A. V., Buryachkovskaya L. I., Vershinina M. G.

Keywords: antiaggregates, acetylsalicylic acid, coronary heart disease, treatment

DOI: 10.18087/rhj.2014.4.2012

Background. Reducing risk for thrombotic complications in IHD patients remains a relevant issue of current pharmacotherapy. Acetylsalicylic acid (ASA) is a first-line drug which keeps a leading place in all guidelines on managing IHD patients. ASA is available in two different forms, the enteric-coated form (enteric) which absorbs in the small intestine, and the form absorbing in the stomach, which contains a non-absorbing antacid (buffered). Despite extensive experience of using ASA, the issue on antiplatelet effects of different ASA forms remains open. Aim. To compare antiplatelet activities of enteric ASA (Thrombo ASS) and ASA + magnesium hydroxide (buffered form, Cardiomagnyl) in stable patients with cardiovascular disease. Materials and methods. This monocenter randomized study included 60 patients (24 males and 36 females) aged 42 to 92 years with stable cardiovascular disease who had indications for ASA in cardioprotective doses according to current guidelines. Parameters of platelet functional activity were tested for 7 days during the buffered ASA (Cardiomagnyl, 75 mg / day, 26 patients) or enteric ASA (Thrombo ASS, 100 mg / day, 33 patients) treatment. Results. The 7day treatments with different ASA forms resulted in significantly decreased platelet aggregation induced by both low (1.0 µМ) and high (5.0 µM) ADP doses, and recovery of the disaggregation phenomenon. During the Cardiomagnyl treatment, platelet activity was significantly reduced compared to the Thrombo ASS treatment. In the group of patients receiving Thrombo ASS, cases of resistance to the medication were observed significantly more frequently than in the Cardiomagnyl treatment group. Cardiomagnyl reduced levels of thromboxane B2 significantly more potently than Throbo ASS (54.4 and 34.7 %, respectively). Conclusion. The compared ASA forms differed by their antiplatelet activities. The buffered ASA form (Cardiomagnyl) exerted a more pronounced antiplatelet effect which was associated with lower resistance than with the enteric-soluble form (Thrombo ASS).
  1. Gibson P. Salicylic acid for coronary thrombosis? Lancet. 1948 Jun 19;1 (6512):965.
  2. Craven L. Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Miss Valley Med J. 1953 Jan;75 (1):38–44.
  3. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. The Canadian Cooperative Study Group. N Engl J Med. 1978 Jul 13;299 (2):53–9.
  4. Fuster V, Sweeny JM. Aspirin: a historical and contemporary therapeutic overview. Circulation. 2011 Feb 22;123 (7):768–78.
  5. Antithrombotic Trialists' Collaboration. Collaborative meta-ana­lysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324 (7329):71–86.
  6. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231 (25):232–5.
  7. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003 Jun 15;110 (5-6):255–8.
  8. Bala M, Chin CN, Logan AT et al. Acetylation of prostaglandin H2 synthases by aspirin is inhibited by redox cycling of the peroxidase. Biochem Pharmacol. 2008 Apr 1;75 (7):1472–81.
  9. Patrono C, Ciabattoni G, Patrignani P et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985 Dec;72 (6):1177–84.
  10. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005 Dec 1;353 (22):2373–83.
  11. Bhatt DL, Scheiman J, Abraham NS et al. ACCF / ACG / AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008 Oct 28;52 (18):1502–17.
  12. Булахова Е. Ю., Кореннова О. Ю., Козырева В. А., Курочкина С. Д. Антиагрегантная терапия больных с ишемической болезнью сердца. Справочник поликлин врача. 2009;9:31–34.
  13. Lin KJ, De Caterina R, García Rodríguez LA. Low-dose aspirin and upper gastrointestinal bleeding in primary versus secondary cardiovascular prevention. Circ Cardiovasc Qual Outcomes. 2014 Jan;7 (1):70–7.
  14. Kelly JP, Kaufman DW, Jurgelon JM et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffe­red product. Lancet. 1996;348 (9039):1413–1416.
  15. Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med. 1991 Oct 17;325 (16):1137–41.
  16. Cattaneo M, Cerletti C, Harrison P et.al. Recommendations for the Standardization of Light Transmission Aggregometry: A Consensus of the Working Party from the Platelet Physiology Subcommittee of SSC / ISTH. J Thromb Haemost. 2013 Apr 10. doi: 10.1111 / jth.12231.
  17. Баркаган З. С., Котовщикова Е. Ф. Сравнительный анализ основных и побочных эффектов различных форм ацетилсалициловой кислоты. Клиническая фармакология и терапия. 2004;13 (3):1–3.
  18. Кукес В. Г., Остроумова О. Д. Кардиомагнил. Новый взгляд на ацетилсалициловую кислоту. Пособие для врачей. 2004
  19. Feldman M, Cryer B. Aspirin absorption rates and platelet inhibition times with 325‑mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution. Am J Cardiol. 1999 Aug 15;84 (4):404–9.
  20. Gantt AJ, Gantt S. Comparison of enteric-coated aspirin and uncoated aspirin effect on bleeding time. Cathet Cardiovasc Diagn. 1998 Dec;45 (4):396–9.
  21. Grosser T, Fries S, Lawson JA et al. Drug resistance and pseudoresistance: An unintended consequence of enteric coating aspirin. Circulation. 2013 Jan 22;127 (3):377–85.
  22. Вёрткин А. Л., Аристархова О. Ю., Адонина Е. В. и др. Безопас­ность и фармакоэкономическая эффективность применения различных препаратов ацетилсалициловой кислоты у пациентов с ИБС. Русский медицинский журнал. 2009;17 (9):1–6.
  23. Taylor DW, Barnett HJ, Haynes RB et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet. 1999;353 (9171):2179–2184.
  24. Which prophylactic aspirin? Drug Ther Bull. 1997 Jan;35 (1):7–8.
Lomakin N. V., Rusanova A. V., Buryachkovskaya L. I. et al. Comparing antiplatelet effects of acetylsalicylic acid in different forms. Russian Heart Journal. 2014;78 (4):206–214

To access this material please log in or register

Register Authorize
Ru En